---
title: Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment
  of High-Risk Newly Diagnosed Multiple Myeloma
date: '2023-09-27'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37753960/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20230927180809&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: 'CONCLUSION: Isa-KRd effectively induces high rates of sustainable MRD
  negativity in the difficult-to-treat HRNDMM population, regardless of transplant
  status, translating into a median PFS that was not yet reached after 44/33 ...'
disable_comments: true
---
CONCLUSION: Isa-KRd effectively induces high rates of sustainable MRD negativity in the difficult-to-treat HRNDMM population, regardless of transplant status, translating into a median PFS that was not yet reached after 44/33 ...